Pulmonary immunization of guinea pigs with diphtheria CRM-197 antigen as nanoparticle aggregate dry powders enhance local and systemic immune responses

AAPS Journal

Volumn 12, Issue 4, 2010, Pages 699-707

  Muttil, Pavan ^a,e   Pulliam, Brian ^b,c   Garcia Contreras, Lucila ^a   Fallon, John Kevin ^a   Wang, Chenchen ^a   Hickey, Anthony James ^a,c   Edwards, David A ^b,c,d  

^a UNC Hamner Institute for Drug Safety Sciences   (United States)

^b HARVARD UNIVERSITY   (United States)

^c Medicine in Need   (United States)

^d HARVARD UNIVERSITY   (United States)

^e UNIVERSITY OF NEW MEXICO   (United States)

Author keywords

CRM 197; Diphtheria vaccine; Dry powder formulation; Guinea pigs; Pulmonary delivery

Indexed keywords

DIPHTHERIA TOXOID CRM197; FORMALDEHYDE; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G ANTIBODY; LEUCINE; NANOPARTICLE; SODIUM CHLORIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; BACTERIAL IMMUNITY; CONTROLLED STUDY; DIPHTHERIA; DRUG DOSAGE FORM COMPARISON; DRUG FORMULATION; DRY POWDER; GUINEA PIG; HISTOPATHOLOGY; IMMUNIZATION; IMMUNOGENICITY; IMMUNOGLOBULIN BLOOD LEVEL; INFLAMMATION; LUNG INJURY; MUCOSAL IMMUNITY; NONHUMAN;

ANIMALS; ANTIBODIES, BACTERIAL; BACTERIAL PROTEINS; BACTERIAL VACCINES; BRONCHOALVEOLAR LAVAGE FLUID; DIPHTHERIA TOXIN; ENZYME-LINKED IMMUNOSORBENT ASSAY; GUINEA PIGS; IMMUNITY, CELLULAR; LACTIC ACID; LUNG; MICROSCOPY, ELECTRON, SCANNING; NANOPARTICLES; NEUTRALIZATION TESTS; POLYGLYCOLIC ACID; POWDERS;

EID: 78649671311     PISSN: 15507416     EISSN: None     Source Type: Journal    
DOI: 10.1208/s12248-010-9229-6     Document Type: Article

References (39)

1. WHO Fact Sheet Number 231. Injection safety, in facts and figures. 2006.
2. MB Rennels MA Deloria ME Pichichero GA Losonsky JA Englund BD Meade EL Anderson MC Steinhoff KM Edwards 2000 Extensive swelling after booster doses of acellular pertussis-tetanus-diphtheria vaccines Pediatrics 105 1 e12 1:STN:280:DC%2BD3c%2FosFertw%3D%3D 10.1542/peds.105.1.e12 10617749
3. H Varmus R Klausner E Zerhouni T Acharya AS Daar PA Singer 2003 Public health. Grand challenges in global health Science 302 5644 398 399 1:CAS:528:DC%2BD3sXotlSgu7c%3D 10.1126/science.1091769 14563993 (Pubitemid 37296252)
4. Janoff EN, Briles DE, Rubins JB. In: Mestecky J et al., editors. Respiratory bacterial vaccines, in mucosal immunology. MA: Elsevier; 2005.
5. SA Moschos VW Bramwell S Somavarapu HO Alpar 2004 Adjuvant synergy: the effects of nasal coadministration of adjuvants Immunol Cell Biol 82 6 628 637 1:CAS:528:DC%2BD2cXhtFakur%2FI 10.1111/j.0818-9641.2004.01280.x 15550121 (Pubitemid 39567324)
6. MJ McCluskie YM Wen Q Di HL Davis 1998 Immunization against hepatitis B virus by mucosal administration of antigen-antibody complexes Viral Immunol 11 4 245 252 1:CAS:528:DyaK1MXitFKgtrw%3D 10.1089/vim.1998.11.245 10189191
7. KS Jaganathan SP Vyas 2006 Strong systemic and mucosal immune responses to surface-modified PLGA microspheres containing recombinant hepatitis B antigen administered intranasally Vaccine 24 19 4201 4211 1:CAS:528: DC%2BD28XksFejs7w%3D 10.1016/j.vaccine.2006.01.011 16446012
8. BN Lambrecht JB Prins HC Hoogsteden 2001 Lung dendritic cells and host immunity to infection Eur Respir J 18 4 692 704 1:CAS:528:DC%2BD3MXpt1Kisr8%3D 11716176
9. C von Garnier L Filgueira M Wikstrom M Smith JA Thomas DH Strickland PG Holt PA Stumbles 2005 Anatomical location determines the distribution and function of dendritic cells and other APCs in the respiratory tract J Immunol 175 3 1609 1618
10. PG Holt 2005 Pulmonary dendritic cells in local immunity to inert and pathogenic antigens in the respiratory tract Proc Am Thorac Soc 2 2 116 120 1:CAS:528:DC%2BD28XhsFGit7w%3D 10.1513/pats.200502-017AW 16113478 (Pubitemid 41233377)
11. L Garcia-Contreras YL Wong P Muttil D Padilla J Sadoff J Derousse WA Germishuizen S Goonesekera K Elbert BR Bloom R Miller PB Fourie A Hickey D Edwards 2008 Immunization by a bacterial aerosol Proc Natl Acad Sci USA 105 12 4656 4660 1:CAS:528:DC%2BD1cXkt12qs7w%3D 10.1073/pnas.0800043105 18344320 (Pubitemid 351753802)
12. M Amidi HC Pellikaan H Hirschberg AH de Boer DJ Crommelin WE Hennink G Kersten W Jiskoot 2007 Diphtheria toxoid-containing microparticulate powder formulations for pulmonary vaccination: preparation, characterization and evaluation in guinea pigs Vaccine 25 37-38 6818 6829 1:CAS:528: DC%2BD2sXpvF2qs7o%3D 10.1016/j.vaccine.2007.05.064 17692440 (Pubitemid 47332722)
13. FT Cutts CJ Clements JV Bennett 1997 Alternative routes of measles immunization: a review Biologicals 25 3 323 338 1:STN:280:DyaK2svmslartw%3D%3D 10.1006/biol.1997.0103 9325001 (Pubitemid 27453255)
14. Muttil P, Prego C, Garcia-Contreras L, Pulliam B, Fallon J, Wang C, Hickey A, et al. Immunization of guinea pigs with novel hepatitis B antigen as nanoparticle aggregate powders administered by the Pulmonary Route. AAPS journal, 2010 (in press).
15. AR Najafabadi K Gilani M Barghi M Rafiee-Tehrani 2004 The effect of vehicle on physical properties and aerosolisation behaviour of disodium cromoglycate microparticles spray dried alone or with l-leucine Int J Pharm 285 1-2 97 108 1:CAS:528:DC%2BD2cXosFSrsb0%3D 10.1016/j.ijpharm.2004.07.027 15488683 (Pubitemid 39361540)
16. HY Li H Neill R Innocent P Seville I Williamson JC Birchall 2003 Enhanced dispersibility and deposition of spray-dried powders for pulmonary gene therapy J Drug Target 11 7 425 432 1:CAS:528:DC%2BD2cXjtFOjs7s%3D 10.1080/ 10611860410001659786 15203931 (Pubitemid 38455828)
17. JC Sung BL Pulliam DA Edwards 2007 Nanoparticles for drug delivery to the lungs Trends Biotechnol 25 12 563 570 1:CAS:528:DC%2BD2sXhtlCru7nK 10.1016/j.tibtech.2007.09.005 17997181 (Pubitemid 350138179)
18. B Pulliam JC Sung DA Edwards 2007 Design of nanoparticle-based dry powder pulmonary vaccines Expert Opin Drug Deliv 4 6 651 663 1:CAS:528: DC%2BD2sXht1elsr3L 10.1517/17425247.4.6.651 17970667 (Pubitemid 350193400)
19. N Orr JE Galen MM Levine 1999 Expression and immunogenicity of a mutant diphtheria toxin molecule, CRM(197), and its fragments in Salmonella typhi vaccine strain CVD 908-htrA Infect Immun 67 8 4290 4294 1:CAS:528: DyaK1MXkvVKltb0%3D 10417208
20. E Papini R Colonna G Schiavo F Cusinato M Tomasi R Rappuoli C Montecucco 1987 Diphtheria toxin and its mutant crm 197 differ in their interaction with lipids FEBS Lett 215 1 73 78 1:CAS:528:DyaL2sXktVagtL0%3D 10.1016/0014-5793(87) 80116-3 3569541 (Pubitemid 17099141)
21. M Porro M Saletti L Nencioni L Tagliaferri I Marsili 1980 Immunogenic correlation between cross-reacting material (CRM197) produced by a mutant of Corynebacterium diphtheriae and diphtheria toxoid J Infect Dis 142 5 716 724 1:CAS:528:DyaL3MXhtVWhsLY%3D 6780629
22. L Illum I Jabbal-Gill M Hinchcliffe AN Fisher SS Davis 2001 Chitosan as a novel nasal delivery system for vaccines Adv Drug Deliv Rev 51 1-3 81 96 1:CAS:528:DC%2BD3MXmtV2ntLc%3D 10.1016/S0169-409X(01)00171-5 11516781 (Pubitemid 32763074)
23. EA McNeela I Jabbal-Gill L Illum M Pizza R Rappuoli A Podda DJ Lewis KH Mills 2004 Intranasal immunization with genetically detoxified diphtheria toxin induces T cell responses in humans: enhancement of Th2 responses and toxin-neutralizing antibodies by formulation with chitosan Vaccine 22 8 909 914 1:CAS:528:DC%2BD2cXhtVOktb4%3D 10.1016/j.vaccine.2003.09.012 15161067 (Pubitemid 38221084)
24. EA McNeela D O'Connor I Jabbal-Gill L Illum SS Davis M Pizza S Peppoloni R Rappuoli KH Mills 2000 A mucosal vaccine against diphtheria: formulation of cross-reacting material (CRM(197)) of diphtheria toxin with chitosan enhances local and systemic antibody and Th2 responses following nasal delivery Vaccine 19 9-10 1188 1198 1:CAS:528:DC%2BD3MXitlCrug%3D%3D 10.1016/S0264-410X(00)00309-1 11137256 (Pubitemid 32008285)
25. KH Mills C Cosgrove EA McNeela A Sexton R Giemza I Jabbal-Gill A Church W Lin L Illum A Podda R Rappuoli M Pizza GE Griffin DJ Lewis 2003 Protective levels of diphtheria-neutralizing antibody induced in healthy volunteers by unilateral priming-boosting intranasal immunization associated with restricted ipsilateral mucosal secretory immunoglobulin a Infect Immun 71 2 726 732 1:CAS:528:DC%2BD3sXovFSmsw%3D%3D 10.1128/IAI.71.2.726-732.2003 12540551 (Pubitemid 36150765)
26. Z Huo R Sinha EA McNeela R Borrow R Giemza C Cosgrove PT Heath KH Mills R Rappuoli GE Griffin DJ Lewis 2005 Induction of protective serum meningococcal bactericidal and diphtheria-neutralizing antibodies and mucosal immunoglobulin A in volunteers by nasal insufflations of the Neisseria meningitidis serogroup C polysaccharide-CRM197 conjugate vaccine mixed with chitosan Infect Immun 73 12 8256 8265 1:CAS:528:DC%2BD2MXhtlertr%2FK 10.1128/IAI.73.12.8256-8265.2005 16299322 (Pubitemid 41740315)
27. H Murakami M Kobayashi H Takeuchi Y Kawashima 1999 Preparation of poly(DL-lactide-co-glycolide) nanoparticles by modified spontaneous emulsification solvent diffusion method Int J Pharm 187 2 143 152 1:CAS:528:DyaK1MXmt1Sgsb4%3D 10.1016/S0378-5173(99)00187-8 10502620 (Pubitemid 29443894)
28. MF Zambaux F Bonneaux R Gref E Dellacherie C Vigneron 1999 Preparation and characterization of protein C-loaded PLA nanoparticles J Control Release 60 2-3 179 188 1:CAS:528:DyaK1MXks1Cqu7Y%3D 10.1016/S0168-3659(99)00073-5 10425324 (Pubitemid 29335944)
29. Department of Health, Education and Welfare. United States minimum requirements: for tetanus and diphtheira toxoid combined precipitated adsorbed (August 25, 1953).
30. D Lu AJ Hickey 2007 Pulmonary vaccine delivery Expert Rev Vaccines 6 2 213 226 1:CAS:528:DC%2BD2sXjvVKjsLc%3D 10.1586/14760584.6.2.213 17408371 (Pubitemid 46607457)
31. K Baraldo E Mori A Bartoloni F Norelli G Grandi R Rappuoli O Finco G Del Giudice 2005 Combined conjugate vaccines: enhanced immunogenicity with the N19 polyepitope as a carrier protein Infect Immun 73 9 5835 5841 1:CAS:528:DC%2BD2MXps1Gktb4%3D 10.1128/IAI.73.9.5835-5841.2005 16113302 (Pubitemid 41193020)
32. RK Gupta RJ Collier R Rappuoli GR Siber 1997 Differences in the immunogenicity of native and formalinized cross-reacting material (CRM197) of diphtheria toxin in mice and guinea pigs and their implications on the development and control of diphtheria vaccine based on CRMs Vaccine 15 12-13 1341 1343 1:CAS:528:DyaK2sXmsVGnu7Y%3D 10.1016/S0264-410X(97)00034-0 9302741 (Pubitemid 27397810)
33. Edelman R. In: O' Hagan DT, editor. An overview of adjuvant use, in vaccine adjuvants: preparation methods and research protocols. New Jersey: Humana; 2000. p. 1-28.
34. H HogenEsch 2002 Mechanisms of stimulation of the immune response by aluminum adjuvants Vaccine 20 Suppl 3 S34 S39 1:CAS:528:DC%2BD38XksVamsb0%3D 10.1016/S0264-410X(02)00169-X 12184362 (Pubitemid 34607673)
35. Singh M, O' Hagan DT. In: Kaufmann SHE, editor. Microparticles as vaccine adjuvants and delivery systems, in novel vaccination strategies. Weinheim: Wiley-VCH; 2004. p. 148-72.
36. Reynolds HY. In: Stein JH, Eisenberg JM, editors. Host defense mechanisms in the respiratory tract, in internal medicine. Philadelphia: Elsevier Health Sciences; 1998. p. 365-70.
37. B Metz W Jiskoot WE Hennink DJ Crommelin GF Kersten 2003 Physicochemical and immunochemical techniques predict the quality of diphtheria toxoid vaccines Vaccine 22 2 156 167 1:CAS:528:DC%2BD3sXovVWmurY%3D 10.1016/j.vaccine.2003.08. 003 14615142 (Pubitemid 37412260)
38. MA Manghi MF Pasetti ML Brero S Deluchi G di Paola V Mathet PV Eriksson 1995 Development of an alternative method for testing the immunogenicity of diphtheria vaccines Vaccine 13 6 597 601 1:STN:280:DyaK28%2FmsFClug%3D%3D 10.1016/0264-410X(94)00047-Q 7483781
39. Department of Health and Human Services, Food and Drug Administration. Biological products; bacterial vaccines and toxoids; implementation of efficacy review; proposed rule. Federal Register. 1985. p. 51002-117